Evidence map›Paper›PMID 41226501›Full record

ReviewInternational journal of molecular sciences2025

Prevalence of Histological Transformation in First-Line Osimertinib Non-Small Cell Lung Cancers: Case Series and Literature Review.

Rebecca Sparavelli, Rossella Bruno, Alessandra Celi, Andrea Sbrana, Iacopo Petrini, Antonio Chella, Clara Ugolini, Greta Alì

Abstract readReviewCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. First-line osimertinib in advancedESMO real world data and digital oncology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rebecca SparavelliSurgical, Medical, Molecular, and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy.ORCID 0009-0004-9178-2120
Rossella BrunoUnit of Pathological Anatomy, University Hospital of Pisa, 56126 Pisa, Italy.
Alessandra CeliSurgical, Medical, Molecular, and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy.
Andrea SbranaPneumo-Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, 50134 Pisa, Italy.ORCID 0000-0003-4460-5282
Iacopo PetriniDepartment of Translational Research and of New Surgical and Medical Technologies, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-7752-6866
Antonio ChellaPneumo-Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, 50134 Pisa, Italy.ORCID 0000-0002-4325-759X
Clara UgoliniSurgical, Medical, Molecular, and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy.
Greta AlìSurgical, Medical, Molecular, and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0001-9258-3466

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with metastatic lung adenocarcinoma (mADC) harboring

Indexed as

AcrylamidesAniline CompoundsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsAdenocarcinoma of LungAdultAgedAged, 80 and overDrug Resistance, NeoplasmErbB ReceptorsFemaleHumansIndolesMaleMiddle AgedAcrylamidesAniline CompoundsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinesTumor Suppressor Protein p53acquired resistanceadenocarcinomaEGFRhistological transformationnon-small cell lung cancerOsimertinib

Identifiers

PMID41226501
PMCPMC12609510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.